Pharmaceuticals company Eris Lifesciences announced Q3FY25 results Q3FY25 consolidated operating revenue up by 50% to Rs 727 crore. Q3FY25 Margin and Fixed Cost Synergies. Gross Margin down by 604 bps due to significant changes in product/ business mix. Fixed Expenses (% of Revenue) down 436 bps YoY. Q3FY25 EBIDTA Rs 250 crore - YoY growth of 43%. Amortisation and Finance costs reflect the full impact of all acquisitions made till date. Book Tax Rate - 25.2% in Q3FY25. OCF-to-EBIDTA ratio - 120% in Q3FY25. Result PDF